Physician profile
Stephen R Wise
NPI 1659373371
$641.83
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $168 · 2021: $245 · 2022: $44.09 · 2023: $17.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $155.83 | 2019-2023 | Reblozyl |
| Lilly USA, LLC | $74.02 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.11 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $60.73 | 2020-2021 | |
| Seagen INC. | $44.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $36.21 | 2019-2020 | |
| Genzyme Corporation | $36.20 | 2021 | |
| Exelixis INC. | $30.40 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.49 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $22.50 | 2020 | |
| Amgen INC. | $21.82 | 2020 | |
| Genentech USA, INC. | $20.54 | 2019 | |
| Taiho Oncology, INC. | $20.12 | 2019 | |
| Epizyme, INC. | $16.66 | 2021 | |
| Boston Scientific Corporation | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.